Karyopharm Therapeutics (KPTI) FCF Margin (2012 - 2025)

Karyopharm Therapeutics (KPTI) has reported FCF Margin for 14 consecutive years, with 34.71% the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, FCF Margin rose 4963.0% year-over-year to 34.71%; the trailing twelve-month figure through Dec 2025 stood at 51.6% (up 3628.0% YoY), and the FY2025 full-year result was 51.6%, up 3628.0% from the prior year.
• FCF Margin declined to 34.71% in Q4 2025 per KPTI's latest filing, from 13.3% in the prior quarter.
• Across five years, FCF Margin topped out at 20.01% in Q4 2021 and bottomed at 246.66% in Q2 2021.
• Historically, FCF Margin has averaged 86.38% across 5 years, with a median of 79.27% in 2022.
• The sharpest annual moves came in 2021 and 2022: FCF Margin tumbled 12643 bps in 2021, then soared 15809 bps in 2022.
• Over 5 years, FCF Margin stood at 20.01% in 2021, then tumbled by 499 bps to 79.94% in 2022, then surged by 31 bps to 55.07% in 2023, then sank by 53 bps to 84.33% in 2024, then soared by 59 bps to 34.71% in 2025.
• According to Business Quant data, FCF Margin over the past three periods registered 34.71%, 13.3%, and 49.29% for Q4 2025, Q3 2025, and Q2 2025 respectively.